Gilead Sciences stock edges lower to $124.30 as FDA reviews new once-weekly HIV PrEP, Gilead Sciences announces

Traders Union
All News
Companies
Gilead Sciences slips 1.03% today

Highlights

Gilead Sciences trades under key moving averages, reflecting persistent selling pressure across multiple timeframes.
Momentum and trend indicators signal continued weakness, with RSI and oscillators indicating a net oversold condition.
Short-term range expected at $121.20–$126.00, with downside risk toward $121 if current bearish sentiment persists.

Persistent selling pressure as major averages cap upside

Gilead Sciences ($GILD) trades at $124.30, below the MA-20 ($129.80), MA-50 ($132.97), and MA-200 ($129.16), indicating persistent selling pressure across short-, medium-, and long-term trends. The Ichimoku Kijun sits at $129.45, acting as immediate resistance. Near-term support is found at the HMA ($123.28), with key support at the year’s prior low ($121.39), while immediate resistance aligns with the Kijun ($129.45) and key resistance sits at MA-50 ($132.97).

Weak momentum with oversold signals after steady weekly decline

Momentum remains weak, with the MACD on D1 projecting a sell signal and the ADX on D1 neutral at low levels, confirming the lack of a clear trend. D1 RSI hovers near 40, joined by oversold readings from CCI and BBP, reflecting net seller dominance and stretched short-term downside after a steady weekly decline. Stoch RSI and BBP also point to an oversold setup, while the AO reinforces the downward direction. In today’s session, $GILD is down 1.03%, underlining persistent bearish sentiment. Over the past week, GILD has fallen $1.29 (1.03%) from the previous close of $125.59, now trading in the lower part of the weekly range. Weekly volatility stands at 6.27%. The week has been marked by a gradual decline from recent highs and a lack of meaningful recovery, in line with momentum signals.

Downside bias as short-term signals favor lower consolidation

Looking ahead, the forecast for next week projects a consolidation range of $121.20 to $126.00, reflecting normalization around current levels and typical volatility. Relative to the 52-week span ($104.46–$157.29), this means prices are well above the yearly low but remain below mid-range. Short-term indicators and W1 momentum (RSI-W1, MACD-W1, ADX-W1, MA-50-W1) do not present any bullish signals, so there is a very low probability (less than 20%) of a sustained upside move, making further downside more likely. Baseline scenario: price fluctuates sideways near the lower end of this corridor. Bullish scenario: a close above resistance at $129.45 could trigger a rapid retest of $132.97. Bearish scenario: sustained weakness below $123.28 would put the $121 zone at risk, increasing the potential for testing 52-week lows if selling intensifies.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Gilead Sciences faced persistent downside pressure with weak technical momentum and limited prospects for a near-term recovery. In light of the latest market developments, investors should monitor for any shifts in sentiment or signs of stabilization that could offer an early signal for a change in the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.